Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P970003/S249

VNS Therapy System

LivaNova USA, Inc. · Decision date Aug 12, 2026

FDA DECISIONP970003/S249

What did the FDA approve?

FDA records P970003/S249 as a supplement to PMA P970003, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 12, 2026.

FDA approval order statement

approval for 1) changing the term partial onset seizures to focal onset seizures in the Indications for Use, 2) changing the term sudden unexplained death to sudden unexpected death, 3) removing the Warning label associated with SUDEP-related information and moving the SUDEP-related information from the Warnings section to the Clinical Studies section of the Physicians Manual, 4) aligning the SUDEP-related information in the Patient Guide with the Physicians Manual and removing the Caution label associated with SUDEP-related information.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Neurology
Decision date
Aug 12, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P970003/S249
Regulatory pathway
PMA supplement
Product code
LYJ
Decision code
APPR
Decision date
Aug 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, autonomic nerve, implanted for epilepsy.

Product code
LYJ
FDA device class
3

For the original device and its historical approval scope, see PMA P970003. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P970003 · Original PMA

    VNS THERAPY SYSTEM

  2. P970003/S249 received

    Application receipt date recorded by FDA.

  3. P970003/S251 · Related supplement

    VNS Therapy Model 3100 Programmer, VNS Therapy Model 2000 Programming Wand

  4. P970003/S249 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P970003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P970003

Product / regulatory recordCompanyPathwayDecision dateSource
LivaNova USA, Inc.PMA approvalJul 16, 1997FDA
VNS Therapy SystemP970003/S248
LivaNova USA, Inc.PMA supplementSep 5, 2025FDA
VNS Therapy SystemP970003/S250
LivaNova USA, Inc.PMA supplementSep 12, 2025FDA
LivaNova USA, Inc.PMA supplementNov 25, 2025FDA
VNS THERAPY SYSTEMP970003/S252
LivaNova USA, Inc.PMA supplementDec 17, 2025FDA
VNS Therapy SystemP970003/S253
LivaNova USA, Inc.PMA supplementMar 4, 2026FDA
VNS Therapy SystemP970003/S254
LivaNova USA, Inc.PMA supplementOct 2, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

LivaNova USA, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
100 Cyberonics Blvd., Houston, TX, 77058

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records